Drug Trial Radar · NCT07918625
A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Aug 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of BGM1812 injection compared with placebo in reducing body weight in overweight or obese participants without diabetes after 26 weeks of treatment.
Conditions
- Overweight or Obese Participants Without Diabetes
Interventions
BGM1812 injection / plcaeboDrug
Once weekly or once every two weeks, administered continuously for 24 weeks.
BGM1812 injection / plcaeboDrug
Once weekly or once every two weeks, administered continuously for 24 weeks.
BGM1812 injection / plcaeboDrug
Once weekly or once every two weeks, administered continuously for 24 weeks.
BGM1812 injection / plcaeboDrug
Once weekly or once every two weeks, administered continuously for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Soochow University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.